The IP6K1 Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the gene encoding inositol hexakisphosphate kinase 1 (IP6K1) has been disrupted. This engineered cell pool provides a genetically heterogeneous loss-of-function model suitable for studying IP6K1-dependent signaling and cellular processes.
The HAP1 cell line is an adherent, near-haploid human cell line originally derived from the KBM-7 chronic myeloid leukemia line (male origin). Its haploid nature facilitates efficient gene targeting and functional genomics studies, making it a widely used platform for knockout screening and mechanistic investigation of gene function.
IP6K1 is a critical kinase that converts inositol hexakisphosphate (IP6) into the inositol pyrophosphates diphosphoinositol pentakisphosphate (IP7) and bis-diphosphoinositol tetrakisphosphate (IP8). IP7 produced by IP6K1 directly binds to the pleckstrin homology (PH) domains of AKT and PDK1, thereby inhibiting AKT-mediated signaling. This modulation affects downstream targets including mTOR, PTEN, and CRTC2, and integrates upstream inputs from insulin, growth factors, and CK2-mediated phosphorylation. IP6K1 also interacts with huntingtin and CK2 to regulate p53-dependent apoptosis and mTORC1 activity, and contributes to actin cytoskeleton dynamics through Grp1 (ARFGEF).
In the near-haploid HAP1 background, disruption of IP6K1 provides a robust system to dissect its role in insulin signaling, apoptosis, and migration without the confounding effects of a diploid genome. The polyclonal nature of this knockout pool captures a range of loss-of-function alleles, enabling the study of phenotypic heterogeneity and dose-dependent effects. This model is particularly valuable for interrogating IP6K1??s function in pathways linked to metabolic disorders and cancer, where HAP1 cells have been previously employed to investigate PI3K/AKT and mTOR signaling.
Key applications include analyzing insulin secretion and AKT phosphorylation by Western blotting, profiling inositol phosphates via HPLC, and assessing cell migration and apoptosis using caspase activation assays. The knockout cells are also suited for co-immunoprecipitation experiments to map IP6K1 interaction partners and for drug target validation studies in type 2 diabetes and cancer metastasis. For further information or technical support regarding the IP6K1 Knockout HAP1 Polyclonal Cells, please contact Ascent Research.
